


WRHA PHN Guidance- Support Tool re: Monkeypox (smallpox) vaccine provision

- [Monkeypox Protocol Quick Reference \(gov.mb.ca\)](#)
- [Monkeypox \(Orthopoxvirus\) Protocol](#) 

PRE-Exposure Eligibility- Updated, *effective* October 6, 2022-

Eligible individuals are:

- Cisgender, transgender or two-spirit people who self-identify as belonging to the gay, bisexual and other men who have sex with men (gbMSM) community and who meet at least one of the following criteria:
 - Have received a diagnosis of a sexually transmitted infection **in the past year**;
 - Have had two or more sexual partners **in the past 90 days**;
 - Have attended locations for sexual contact (e.g. bath houses or sex clubs) or are planning to;
 - Have had anonymous sex **in the past 90 days** (i.e. using apps, online sites, formal/informal gatherings) or are planning to;
 - Engaged in sex work or plan to, as a worker or client; or
- Any sexual contacts of the individuals described above
- Individuals who self-identify as sex workers, *regardless* of self-identified sex/gender
- Staff or volunteers in sex-on-premises venues where workers may have contact with objects or materials that may be contaminated with the monkeypox virus without the use of personal protective equipment (PPE)

These individuals will also be eligible for a 2nd dose of vaccine, given at least 28 days after the 1st dose, to complete their Imvamune[®] vaccine series.

POST-Exposure Eligibility

Eligible individuals are those persons who answer yes to *either* question below:

- Close contacts of a confirmed or probable monkeypox case

Vaccination used for pre-exposure prophylaxis may help prevent the onset of the disease or make it less severe. At this time, due to the limited national and global vaccine supply, pre-exposure prophylaxis will consist of a single dose of vaccine

Eligibility will be updated as required on the Manitoba monkeypox website.

The vaccine is NOT indicated for those with signs and symptoms of monkeypox.

- [WRHA Imms Program CPG: 1 \(wrha.mb.ca\)](#)
- **IMVAMUNE®**- Smallpox and Monkeypox Vaccine-
Modified Vaccinia Ankara-Bavarian Nordic® (live-attenuated, non-replicating)
 - [Imvamune NACI Quick Reference Guide](#)
 - **Contraindications, Serious Warnings and Precautions:**

Contraindications	<ul style="list-style-type: none"> • Patients who are hypersensitive to this vaccine or to any ingredient in the formulation or component of the container. • Individuals who show hypersensitivity reactions after receiving the first dose of the vaccine should not be given the second dose. • As with other vaccines, vaccination with IMVAMUNE® must be postponed in persons with acute febrile conditions if used for non-emergency (pre-event) prophylaxis.
--------------------------	--

National Advisory Committee on Immunization (NACI) recommendation for Special Populations:

<https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/guidance-imvamune-monkeypox/guidance-imvamune-monkeypox-en.pdf>

NACI recommends that Imvamune® vaccine may be offered to the following populations, if recommended to receive vaccine based on exposure risk:

- **Individuals who are Immunocompromised due to disease or treatment**
- **Individuals who are pregnant**
- **Individuals who are lactating**
- **Children and youth <18 years of age**
- **Individuals with atopic dermatitis**

(Discretionary NACI Recommendation)

****** Review Special Populations individuals with CDC wrhacdcoordinators@wrha.mb.ca who will consult with MoH as needed****** PreP immunization clinics that began the week of August 8, 2022 continue to be reserved for 18 years of age and older.

Smallpox and Monkeypox Vaccine (IMVAMUNE®) Product Monograph:

- [Imvamune Product Monograph](#)
 - Once the vaccine has been received from the Vaccine Warehouse, promptly transfer to a temperature-monitored refrigerator at +2°C to +8°C. It can be stored for up to two weeks/14 days (record the new expiry date on the vial prior to commencing refrigeration storage) and should be kept in the original packaging and protected from light.
 - Do not refreeze thawed vials.
 - If removing from freezer storage for use, thaw at refrigeration or room temperature.
 - A vial of vaccine will take approximately 5 minutes to thaw at room temperature if it is still in its frozen state.
 - PHN to remove one vial from the designated refrigerator or portable equipped hard-sided cooler once client confirmed to be fit to be immunized. Draw-up per client *only*. Do NOT have multiple vials out at room temperature in advance.

- Gently swirl vaccine upon thawing for at least 30 seconds to ensure homogeneity; **do not shake.**
- Once thawed, the vaccine will appear as a pale milky coloured homogeneous suspension.
 - Inspect vial to confirm there is no foreign particulate matter. If any is observed do not administer the vaccine
- No reconstitution required

➤ **Manitoba Health Vaccination Clinic Resources (Manitoba Health):**

- [Adult Immunization Consent Form \(manitoba.ca\)](#) - In your assessment please inquire about breastfeeding when reviewing question 6
- [Monkeypox Vaccine \(gov.mb.ca\)](#)
- [Monkeypox case and contact management factsheet \(gov.mb.ca\)](#)

➤ **Vaccination Clinic Resources (PHAC):**

- [Monkeypox: Vaccination clinic resources - Canada.ca](#) *Information sheet*
- [Monkeypox: Vaccination clinic resources - Canada.ca](#) *After Care sheet*

➤ **Dose & Product Guidance:**

PRE-Exposure Prophylaxis: Dose 1 given as 0.5 ml SC.



Dose 2 also given as 0.5 ml SC at least 28 days from Dose 1.

POST-Exposure Prophylaxis: 1 dose given as 0.5 mL SC. Consider 2nd dose 4 weeks later if ongoing risk of exposure in consultation with public health.

- ❖ Those who have previously been vaccinated against smallpox (2 years ago or more) should receive 1 dose of PreP or PEP as applicable.

Instruction for flipping off cap for Imvamune

- Withdraw with a syringe and needle long enough to reach the bottom of the vial.
- For injection, needle should be changed to a subcutaneous injection needle
- Use a 25-27 gauge 5/8"-7/8" needle for subcutaneous injections.
- Sites for subcutaneous injection are the lateral aspect of the upper arm and the fatty area of the anterolateral thigh. [The thigh is the site of choice for infants < 12 months of age and the upper outer triceps area is recommended for all individuals ≥ 12 months].
- Insert the needle at a 45-degree angle.



- **Concomitant administration (as per Provincial Clinic Reference):** If vaccine timing can be planned (i.e. prior to employment within a research laboratory), NACI recommends that Imvamune® be given at least 4 weeks after or before an mRNA vaccine for COVID-19;

Imvamune® given as PEP or PrEP should not be delayed due to recent receipt of an mRNA COVID-19 vaccine.

Interactions with other vaccines have not been established. Therefore, concomitant administration of other vaccines should be avoided. If co-administration with another vaccine is indicated, immunization should be carried out on separate limbs.

- ❖ **Note:** Manitoba Health’s Monkeypox Vaccine fact sheet:

Generally, the monkeypox vaccine should not be given at the same time as other (live or inactivated) vaccines, and you should wait two to four weeks before receiving or getting another vaccine.

Therefore, if an eligible individual is persistent and understands the benefit vs risks in receiving IMVAMUNE® vaccine < minimum interval of 2 weeks, then the word “*should*” implies they *can* be immunized. ***provided there is appropriate documentation of the informed consent***.

- PHIMS how-to's re: **MASS EVENT ID(s) #** _____
(PetalMD will equip the CD Unit with the appointment sheet which will be forwarded to the involved PHNs)

[Immunizations \(phimsmb.ca\)](http://phimsmb.ca)

3. Mass Immunization Event

- ❖ PHN assessment (*eligibility confirmation and health history) will be done with all clients on the worksheet.
- ❖ Even those that do not meet eligibility criteria will require a clinical note in PHIMS indicating same.
-i.e. P): Following PHN risk assessment and health history, client does not meet eligibility criteria. No further PH follow-up required...or advised A / B / C.- signature & designation
- ❖ PHN to keep CDC apprised of IMVAMUNE® stock, any wastage, vaccine supplies status (if warranted) and # clients being immunized daily.

➤ **Validation:**

- Manitoba Health Communicable Disease Control & Immunization re: Monkeypox
- National Advisory Committee on Immunization (NACI) re: Imvamune
- BC Immunization Manual, BC Centre for Disease Control
- PHAC Monkeypox: Vaccination clinic resources